Inlyta

Chemical Nameaxitinib
Dosage FormTablets (oral; 1mg, 5mg)
Drug ClassKinase inhibitors
SystemUrinary
CompanyPfizer
Approval Year2012

Indication

  • For the treatment of advanced renal cell carcinoma after failure of one prior systemic therapy.
Last updated on 5/10/2021

More on this drug: Clinical Trials

Have we missed a study, or would you like to comment on a study?

Document TitleYearSource
Inlyta (axitinib) Prescribing Information2012Pfizer Inc., New York, NY
Document TitleYearSource
Systemic therapy for metastatic renal cell carcinoma in the first‑line setting: a systematic review and network meta‑analysis.2021Cancer Immunology, Immunotherapy
Targeted therapy for metastatic renal cell carcinoma. 2020Cochrane Database of Systematic Reviews
What is the optimum systemic treatment for advanced/metastatic renal cell carcinoma of favourable, intermediate and poor risk, respectively? A systematic review and network meta-analysis.2020BMJ Open
First-line treatments for advanced renal cell carcinoma with immune checkpoint inhibitors: systematic review, network meta-analysis and cost-effectiveness analysis.2020Therapeutic Advances in Medical Oncology
Comparative efficacy of first-line immune-based combination therapies in metastatic renal cell carcinoma: A systematic review and network meta-analysis.2020Cancers
The clinical significance of routine risk categorization in metastatic renal cell carcinoma and its impact on treatment decision-making: a systematic review.2020Future Oncology
First-line treatment of metastatic renal cell carcinoma: A systematic review and network meta-analysis.2019European Urology
Role of immune checkpoint inhibitor-based therapies for metastatic renal cell carcinoma in the first-line setting: A Bayesian network analysis.2019EBioMedicine
Targeted therapies for previously treated advanced or metastatic renal cell carcinoma: systematic review and network meta-analysis.2019BMJ Open
First-line systemic therapy for metastatic renal cell carcinoma: A systematic review and network meta-analysis. 2018European Urology
Cabozantinib versus everolimus, nivolumab, axitinib, sorafenib and best supportive care: A network meta-analysis of progression-freesurvival and overall survival in second line treatment of advanced renal cell carcinoma.2017PLoS One
Comparative efficacy and safety of axitinib versus sorafenib in metastatic renal cell carcinoma: a systematic review and meta-analysis.2016OncoTargets and Therapy
Document TitleYearSource
EAU guidelines on renal cell carcinoma.2021European Association of Urology
Kidney cancer, version 1.2021.2020Journal of the National Comprehensive Cancer Network